WO2022191184A1 - グレリン受容体感受性増強剤、グレリン受容体感受性増強用組成物及びグレリン受容体の活性化方法 - Google Patents

グレリン受容体感受性増強剤、グレリン受容体感受性増強用組成物及びグレリン受容体の活性化方法 Download PDF

Info

Publication number
WO2022191184A1
WO2022191184A1 PCT/JP2022/009999 JP2022009999W WO2022191184A1 WO 2022191184 A1 WO2022191184 A1 WO 2022191184A1 JP 2022009999 W JP2022009999 W JP 2022009999W WO 2022191184 A1 WO2022191184 A1 WO 2022191184A1
Authority
WO
WIPO (PCT)
Prior art keywords
ornithine
ghrelin
ghrelin receptor
salt
improvement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2022/009999
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
しのぶ 安尾
幸宏 菱田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyushu University NUC
Kyowa Hakko Bio Co Ltd
Original Assignee
Kyushu University NUC
Kyowa Hakko Bio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyushu University NUC, Kyowa Hakko Bio Co Ltd filed Critical Kyushu University NUC
Priority to JP2023505576A priority Critical patent/JPWO2022191184A1/ja
Publication of WO2022191184A1 publication Critical patent/WO2022191184A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • ornithine salts include acid addition salts, metal salts, ammonium salts, organic amine addition salts and amino acid addition salts.
  • Acid addition salts include, for example, inorganic acid salts such as hydrochlorides, sulfates, nitrates and phosphates, as well as acetates, maleates, fumarates, citrates, malate, lactates, ⁇ - Organic acid salts such as ketoglutarate, gluconate and caprylate are included.
  • a dosage form suitable for parenteral administration in the case of an injection, preferably consists of a sterile aqueous preparation containing ornithine or a salt thereof that is isotonic with the blood of the recipient.
  • injectable solutions for example, may be prepared using carriers comprising saline, dextrose solution, or a mixture of saline and dextrose solution, and the like.
  • additives generally used in food and drink may be added to formulations suitable for oral administration. Additives include, for example, sweeteners, coloring agents, preservatives, thickening stabilizers, antioxidants, color formers, bleaching agents, antifungal agents, gum bases, bittering agents, enzymes, brighteners, acidulants, and seasonings. , emulsifiers, fortifying agents, manufacturing agents, flavoring and spice extracts.
  • the present invention includes methods for administering ornithine or salts thereof.
  • the method of administering ornithine or a salt thereof of the present invention is effective for improving memory, improving dementia, neurogenesis, neuroprotection against neurodegeneration, regulation of cardiovascular function, promotion of osteoblast proliferation, promotion of bone formation, prevention of heart failure and chronic obstructive pulmonary disease. administering to the subject an effective amount of ornithine or a salt thereof for use in at least one selected from disease amelioration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/JP2022/009999 2021-03-08 2022-03-08 グレリン受容体感受性増強剤、グレリン受容体感受性増強用組成物及びグレリン受容体の活性化方法 Ceased WO2022191184A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023505576A JPWO2022191184A1 (https=) 2021-03-08 2022-03-08

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-036519 2021-03-08
JP2021036519 2021-03-08

Publications (1)

Publication Number Publication Date
WO2022191184A1 true WO2022191184A1 (ja) 2022-09-15

Family

ID=83227961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/009999 Ceased WO2022191184A1 (ja) 2021-03-08 2022-03-08 グレリン受容体感受性増強剤、グレリン受容体感受性増強用組成物及びグレリン受容体の活性化方法

Country Status (2)

Country Link
JP (1) JPWO2022191184A1 (https=)
WO (1) WO2022191184A1 (https=)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007049628A1 (ja) * 2005-10-25 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. 血液流動性改善剤
WO2007088681A1 (ja) * 2006-01-31 2007-08-09 National University Corporation Hokkaido University グレリン産生促進剤
JP2011508773A (ja) * 2008-01-04 2011-03-17 ネステク ソシエテ アノニム 不飽和脂肪酸及び酸化窒素放出化合物を含む組成物、並びに認知機能及び関連の機能を高めるためのそれらの使用
WO2013129642A1 (ja) * 2012-03-02 2013-09-06 協和発酵バイオ株式会社 摂食活動および／または消化管活動促進剤
WO2015199192A1 (ja) * 2014-06-25 2015-12-30 株式会社明治 グレリン分泌促進剤
WO2021200996A1 (ja) * 2020-03-30 2021-10-07 味の素株式会社 骨強度低下の予防又は改善用組成物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007049628A1 (ja) * 2005-10-25 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. 血液流動性改善剤
WO2007088681A1 (ja) * 2006-01-31 2007-08-09 National University Corporation Hokkaido University グレリン産生促進剤
JP2011508773A (ja) * 2008-01-04 2011-03-17 ネステク ソシエテ アノニム 不飽和脂肪酸及び酸化窒素放出化合物を含む組成物、並びに認知機能及び関連の機能を高めるためのそれらの使用
WO2013129642A1 (ja) * 2012-03-02 2013-09-06 協和発酵バイオ株式会社 摂食活動および／または消化管活動促進剤
WO2015199192A1 (ja) * 2014-06-25 2015-12-30 株式会社明治 グレリン分泌促進剤
WO2021200996A1 (ja) * 2020-03-30 2021-10-07 味の素株式会社 骨強度低下の予防又は改善用組成物

Also Published As

Publication number Publication date
JPWO2022191184A1 (https=) 2022-09-15

Similar Documents

Publication Publication Date Title
JP6255079B2 (ja) シトルリンおよびアルギニンを含有する即効性血中アルギニン濃度上昇型経口剤
KR20210036293A (ko) 유청단백 가수분해물을 유효성분으로 함유하는 근감소증의 개선, 예방 또는 치료용 조성물
US20100234308A1 (en) Wake-up remedy
WO2007142286A1 (ja) 疲労軽減剤
US9119416B2 (en) Muscle fatigue remedy
JP5188181B2 (ja) 血中アルコール濃度上昇抑制用組成物
JP2010018522A (ja) アディポネクチン産生促進剤
JP2009526748A (ja) カルシウム吸収促進剤
JPWO2015137387A1 (ja) 筋肉増強剤
US20170281582A1 (en) Enhancer for eating activity and/or gastrointestinal activity
WO2022191184A1 (ja) グレリン受容体感受性増強剤、グレリン受容体感受性増強用組成物及びグレリン受容体の活性化方法
JP2025517146A (ja) 軟骨変性における使用のための、フィセチン及びケルセチンの組み合わせを使用した組成物及び方法
JP2025515591A (ja) 軟骨変性における使用のための、オレウロペイン及びフィセチンの組み合わせを使用した組成物及び方法
WO2015118699A1 (ja) 満腹感持続剤および満足感を維持する方法
RU2670612C2 (ru) Композиция для предупреждения или лечения ожирения, содержащая α-липоевую кислоту и N-ацетилцистеин в качестве активных ингредиентов
JP6594858B2 (ja) メラトニン分泌調整剤、メラトニン分泌調整方法
JP2024508699A (ja) シクロ－ｌ－フェニルアラニル－ｌ－プロリンジペプチドを含む筋線維形成の促進または破骨細胞の分化抑制メカニズムによるサルコペニアまたは骨粗鬆症の治療用組成物
TWI864612B (zh) 具有抗肥胖與抗糖尿病活性的胜肽、包含其之醫藥組成物及包含其之機能性食品組成物
KR20150131477A (ko) 설포라판 유도체를 유효성분으로 함유하는 당뇨병 예방 및 치료용 조성물
JPWO2009054360A1 (ja) 内臓脂肪特異的低減剤
JP2010095474A (ja) カルシウム吸収促進組成物及びカルシウム吸収促進飲食物
US20060258746A1 (en) Oral medicament for improvement in going to sleep or waking
JP2015205829A (ja) ホルモン分泌促進剤
JP2008255087A (ja) 自発運動促進剤
KR20240054436A (ko) 근기능 개선활성을 갖는 펩타이드 및 이를 포함하는 근감소증의 개선, 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22767138

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023505576

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22767138

Country of ref document: EP

Kind code of ref document: A1